.37/.43 on otc bb, 6.8m shares out:
ZymeTx Receives Major ZstatFlu Order From Japan
Nichirei Orders Rapid Flu Diagnostic Tests for Distribution in Japanese Market
OKLAHOMA CITY--(BW HealthWire)--July 12, 2001--ZymeTx, Inc. (OTCBB:ZMTX - news) announced today it finalized the sale of 100,000 ZstatFlu® diagnostic test units to its Japanese distributor, the Nichirei Corporation, Tokyo, Japan.
The sale represents the single-largest bulk order received by ZymeTx for its ZstatFlu influenza diagnostic test since the company introduced the rapid point-of-care test in 1998. A biotech company engaged in viral disease detection, diagnosis and management, ZymeTx will deliver the test units in partial shipments over the next five months.
``The sale signals a major leap forward in our strategic pursuit of building a solid presence in selected international markets,'' commented Norman Proulx, ZymeTx President and Chief Executive Officer. ``We believe the Japan market represents an opportunity to gain important momentum leading into the 2001/2002 winter flu season.''
The Japan Ministry of Health, Labor and Welfare approved ZstatFlu for sale in Japan this March. Nichirei Corporation Biomedical Sciences Division managed the ZstatFlu approval process in Japan for ZymeTx. The regulatory approval occurred shortly after the United States Food and Drug Administration (FDA) granted CLIA waived status to ZstatFlu, allowing usage of the test in non-laboratory medical settings.
Nichirei's substantial order permits them to position ZstatFlu as the leading flu diagnostic test in the Japanese market and to fulfill expected commitments from hospitals and doctors in the coming months.
Continuous improvements over the past three years since ZstatFlu's introduction have resulted in a test that takes 20 minutes or less and has a 99-percent specificity rate on positive results, based on actual clinical trials. ZstatFlu is the world's first rapid point-of-care flu diagnostic test for the detection of both Influenza A and B viruses.
``We are extremely pleased and encouraged with the long-term opportunity of expanding this new viral detection technology for influenza in Japan with Nichirei Corporation,'' said Craig D. Shimasaki, ZymeTx Vice President of Research, Development and Operations. ``We have been able to work effectively and expeditiously with Nichirei in both the ZstatFlu approval process and in strategic marketing efforts in Japan.''
``We look forward to implementing ZstatFlu in a comprehensive viral disease management system for influenza in Japan as it is particularly important in high-density populations,'' commented Dr. Robert Hudson, ZymeTx's Medical Director. ``Our research studies and industry statistics confirm that healthcare costs are reduced and quality of care is improved when ZstatFlu is introduced into the viral disease management system.''
About the Companies
ZymeTx, Inc. is a biotechnology company engaged in the development of technology to produce products for the diagnosis and treatment of viral disease, viral management and disease surveillance. The company developed ZstatFlu, the world's first rapid point-of-care test capable of detecting both Influenza A and B, and the National Flu Surveillance Network(TM) (NFSN), a network of physician sites across the country that use ZstatFlu to track influenza in their communities and practices. The common stock of ZymeTx, Inc. (OTCBB) is traded under the symbol ``ZMTX''. Additional information on ZymeTx and NFSN can be obtained by accessing the web sites at www.zymetx.com and www.fluwatch.com.
Nichirei Corporation's Biosciences Business Division supports a wide range of research and development programs and biotechnology research for one of Japan's leading food product companies. Nichirei's operations include domestic and international production, processing, distribution and storage.
(BSNS WIRE) National Association of Community Health Centers and ZymeTx to
National Association of Community Health Centers and ZymeTx to Promote ZstatFlu
Business/Health Editors & Medical Writers
OKLAHOMA CITY--(BW HealthWire)--July 2, 2001--ZymeTx, Inc.
(OTCBB:ZMTX):
Agreement Expands ZstatFlu Availability into New Market Segment
And Utilizes MedCenterDirect Electronic Distribution System
The nation's largest trade association serving America's poor and
medically underserved, the National Association of Community Health
Centers (NACHC), with ZymeTx (OTCBB: ZMTX) will offer the Company's
ZstatFlu(R) influenza diagnostic test to the 3,200 health center sites
across the United States.
"This relationship establishes a product presence for ZstatFlu
within a medically vulnerable segment of America's population, where
unchecked flu can spur serious unintended health and financial
consequences," observed Norman Proulx, President and Chief Executive
Officer of ZymeTx, Inc. "Our alignment with the NACHC advances
ZymeTx's strategic initiative to support organizations charged with
health care responsibilities for significant population bases. This
arrangement creates the potential for repetitive long-term, multi-unit
sales opportunities for ZstatFlu," Proulx said.
Community Health Centers service 11 million people at delivery
sites in all 50 states, the District of Columbia, Puerto Rico, Guam
and the U.S. Virgin Islands. Community Health Centers strive to
address access problems in areas with few or no physicians and other
health and social services.
The partnership complements the broad initiative on behalf of the
NACHC and Community Health Centers to establish an influenza disease
management program at the grassroots level.
"The utilization of a rapid influenza diagnostic test is the first
line of defense to prevent the spread of flu among this susceptible
segment of our population," stated Dr. Tom Curtin, NACHC Chief Medical
Officer. "The use of this test can lower health care costs while at
the same time improve the overall quality of care."
"The agreement with ZymeTx for ZstatFlu is consistent with the
NACHC's mission to promote and deliver quality health care to the
medically underserved populations. ZstatFlu offers a proven method to
detect flu so it can be properly and promptly treated," Curtin
commented.
ZstatFlu is the first FDA-approved rapid flu diagnostic test to
detect both Influenza A and B from a throat swab specimen with
99-percent specificity on positive tests, based on actual clinical
trials. The test, which produces results in 20 minutes, will serve as
the centerpiece of a new NACHC Influenza Starter Kit. Community Health
Centers will receive kits for the 2001/2002 winter flu season.
The agreement designates MedCenterDirect as the exclusive
electronic distributor of ZstatFlu to Community Health Centers, which
will order ZstatFlu tests through the MedCenterDirect web site at
www.medcenterdirect.com.
"MedCenterDirect will play a very important role in the success of
this initiative by providing a highly efficient ordering process to
ensure the timely delivery of products to Community Health Centers,"
stated Proulx.
MedCenterDirect links clinicians and suppliers through Internet
e-commerce technology. "MedCenterDirect streamlines administrative and
financial functions for providers," said Dr. Curtin. "Its cost-savings
system will allow Community Health Centers to more effectively manage
their medical inventories."
About the Organizations
ZymeTx, Inc., headquartered in Oklahoma City, is a biotechnology
company engaged in the development of technology to produce products
for the diagnosis and treatment of viral disease, viral management and
disease surveillance. The company developed ZstatFlu, the world's
first rapid point-of-care test capable of detecting both Influenza A
and B, and the National Flu Surveillance Network(TM), a network of
physician sites across the country that use ZstatFlu to track
influenza in their communities and practices. Additional information
on ZymeTx and NFSN can be obtained by accessing the web sites at
www.zymetx.com and www.fluwatch.com.
The National Association of Community Health Centers is the
national trade association serving and representing the interests of
America's Community Health Centers, private, not-for-profit,
consumer-directed health care corporations which provide high-quality,
cost-effective and comprehensive primary and preventive care to
medically underserved and uninsured people. This nationwide network of
safety net providers is primarily comprised of health centers which
are supported by federal grants under the U.S. Public Health Service
Act: Community Health Centers, Migrant Health Centers, Health Care for
the Homeless Programs and Public Housing Primary Care Programs.
MedCenterDirect is a leading, fully operational cost management
system giving healthcare providers innovative, cost-effective ways to
purchase healthcare products and supplies. MedCenterDirect's fully
integrated cost management platform links clinicians and
administrators with suppliers in a clinically focused, efficient
procurement process. By electronically streamlining purchasing and
inventory control, it allows caregivers to focus on higher-quality
patient care and administrators to lower costs, improve inventory
turns and ensure purchasing contract compliance. It also provides a
new financial management tool enabling comprehensive analysis of cost
per procedure by a physician, a facility, or an entire health care
network.
This press release may contain forward-looking statements
including statements regarding expected future results of operations,
which are subject to risks and uncertainties. All forward-looking
statements in this press release are based upon historical information
available as of the date of this release. Such historic information
may change or become invalid after the date of this release, and by
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release. The Company's SEC filings contain additional
discussions about those facts, which could cause actual results to
differ from management's expectations.
--30--LVD/dx*
CONTACT: ZymeTx, Inc.
Susan Hammond, 405/271-1314
www.zymetx.com
or
The Gooden Group, Inc.
Media Relations: Brent Gooden, 405/715-3232
KEYWORD: OKLAHOMA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
(BSNS WIRE) National Association of Community Health Centers and ZymeTx to
National Association of Community Health Centers and ZymeTx to Promote ZstatFlu
Business/Health Editors & Medical Writers
OKLAHOMA CITY--(BW HealthWire)--July 2, 2001--ZymeTx, Inc.
(OTCBB:ZMTX):
Agreement Expands ZstatFlu Availability into New Market Segment
And Utilizes MedCenterDirect Electronic Distribution System
The nation's largest trade association serving America's poor and
medically underserved, the National Association of Community Health
Centers (NACHC), with ZymeTx (OTCBB: ZMTX) will offer the Company's
ZstatFlu(R) influenza diagnostic test to the 3,200 health center sites
across the United States.
"This relationship establishes a product presence for ZstatFlu
within a medically vulnerable segment of America's population, where
unchecked flu can spur serious unintended health and financial
consequences," observed Norman Proulx, President and Chief Executive
Officer of ZymeTx, Inc. "Our alignment with the NACHC advances
ZymeTx's strategic initiative to support organizations charged with
health care responsibilities for significant population bases. This
arrangement creates the potential for repetitive long-term, multi-unit
sales opportunities for ZstatFlu," Proulx said.
Community Health Centers service 11 million people at delivery
sites in all 50 states, the District of Columbia, Puerto Rico, Guam
and the U.S. Virgin Islands. Community Health Centers strive to
address access problems in areas with few or no physicians and other
health and social services.
The partnership complements the broad initiative on behalf of the
NACHC and Community Health Centers to establish an influenza disease
management program at the grassroots level.
"The utilization of a rapid influenza diagnostic test is the first
line of defense to prevent the spread of flu among this susceptible
segment of our population," stated Dr. Tom Curtin, NACHC Chief Medical
Officer. "The use of this test can lower health care costs while at
the same time improve the overall quality of care."
"The agreement with ZymeTx for ZstatFlu is consistent with the
NACHC's mission to promote and deliver quality health care to the
medically underserved populations. ZstatFlu offers a proven method to
detect flu so it can be properly and promptly treated," Curtin
commented.
ZstatFlu is the first FDA-approved rapid flu diagnostic test to
detect both Influenza A and B from a throat swab specimen with
99-percent specificity on positive tests, based on actual clinical
trials. The test, which produces results in 20 minutes, will serve as
the centerpiece of a new NACHC Influenza Starter Kit. Community Health
Centers will receive kits for the 2001/2002 winter flu season.
The agreement designates MedCenterDirect as the exclusive
electronic distributor of ZstatFlu to Community Health Centers, which
will order ZstatFlu tests through the MedCenterDirect web site at
www.medcenterdirect.com.
"MedCenterDirect will play a very important role in the success of
this initiative by providing a highly efficient ordering process to
ensure the timely delivery of products to Community Health Centers,"
stated Proulx.
MedCenterDirect links clinicians and suppliers through Internet
e-commerce technology. "MedCenterDirect streamlines administrative and
financial functions for providers," said Dr. Curtin. "Its cost-savings
system will allow Community Health Centers to more effectively manage
their medical inventories."
About the Organizations
ZymeTx, Inc., headquartered in Oklahoma City, is a biotechnology
company engaged in the development of technology to produce products
for the diagnosis and treatment of viral disease, viral management and
disease surveillance. The company developed ZstatFlu, the world's
first rapid point-of-care test capable of detecting both Influenza A
and B, and the National Flu Surveillance Network(TM), a network of
physician sites across the country that use ZstatFlu to track
influenza in their communities and practices. Additional information
on ZymeTx and NFSN can be obtained by accessing the web sites at
www.zymetx.com and www.fluwatch.com.
The National Association of Community Health Centers is the
national trade association serving and representing the interests of
America's Community Health Centers, private, not-for-profit,
consumer-directed health care corporations which provide high-quality,
cost-effective and comprehensive primary and preventive care to
medically underserved and uninsured people. This nationwide network of
safety net providers is primarily comprised of health centers which
are supported by federal grants under the U.S. Public Health Service
Act: Community Health Centers, Migrant Health Centers, Health Care for
the Homeless Programs and Public Housing Primary Care Programs.
MedCenterDirect is a leading, fully operational cost management
system giving healthcare providers innovative, cost-effective ways to
purchase healthcare products and supplies. MedCenterDirect's fully
integrated cost management platform links clinicians and
administrators with suppliers in a clinically focused, efficient
procurement process. By electronically streamlining purchasing and
inventory control, it allows caregivers to focus on higher-quality
patient care and administrators to lower costs, improve inventory
turns and ensure purchasing contract compliance. It also provides a
new financial management tool enabling comprehensive analysis of cost
per procedure by a physician, a facility, or an entire health care
network.
This press release may contain forward-looking statements
including statements regarding expected future results of operations,
which are subject to risks and uncertainties. All forward-looking
statements in this press release are based upon historical information
available as of the date of this release. Such historic information
may change or become invalid after the date of this release, and by
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release. The Company's SEC filings contain additional
discussions about those facts, which could cause actual results to
differ from management's expectations.
--30--LVD/dx*
CONTACT: ZymeTx, Inc.
Susan Hammond, 405/271-1314
www.zymetx.com
or
The Gooden Group, Inc.
Media Relations: Brent Gooden, 405/715-3232
KEYWORD: OKLAHOMA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
(BSNS WIRE) National Association of Community Health Centers and ZymeTx to
National Association of Community Health Centers and ZymeTx to Promote ZstatFlu
Business/Health Editors & Medical Writers
OKLAHOMA CITY--(BW HealthWire)--July 2, 2001--ZymeTx, Inc.
(OTCBB:ZMTX):
Agreement Expands ZstatFlu Availability into New Market Segment
And Utilizes MedCenterDirect Electronic Distribution System
The nation's largest trade association serving America's poor and
medically underserved, the National Association of Community Health
Centers (NACHC), with ZymeTx (OTCBB: ZMTX) will offer the Company's
ZstatFlu(R) influenza diagnostic test to the 3,200 health center sites
across the United States.
"This relationship establishes a product presence for ZstatFlu
within a medically vulnerable segment of America's population, where
unchecked flu can spur serious unintended health and financial
consequences," observed Norman Proulx, President and Chief Executive
Officer of ZymeTx, Inc. "Our alignment with the NACHC advances
ZymeTx's strategic initiative to support organizations charged with
health care responsibilities for significant population bases. This
arrangement creates the potential for repetitive long-term, multi-unit
sales opportunities for ZstatFlu," Proulx said.
Community Health Centers service 11 million people at delivery
sites in all 50 states, the District of Columbia, Puerto Rico, Guam
and the U.S. Virgin Islands. Community Health Centers strive to
address access problems in areas with few or no physicians and other
health and social services.
The partnership complements the broad initiative on behalf of the
NACHC and Community Health Centers to establish an influenza disease
management program at the grassroots level.
"The utilization of a rapid influenza diagnostic test is the first
line of defense to prevent the spread of flu among this susceptible
segment of our population," stated Dr. Tom Curtin, NACHC Chief Medical
Officer. "The use of this test can lower health care costs while at
the same time improve the overall quality of care."
"The agreement with ZymeTx for ZstatFlu is consistent with the
NACHC's mission to promote and deliver quality health care to the
medically underserved populations. ZstatFlu offers a proven method to
detect flu so it can be properly and promptly treated," Curtin
commented.
ZstatFlu is the first FDA-approved rapid flu diagnostic test to
detect both Influenza A and B from a throat swab specimen with
99-percent specificity on positive tests, based on actual clinical
trials. The test, which produces results in 20 minutes, will serve as
the centerpiece of a new NACHC Influenza Starter Kit. Community Health
Centers will receive kits for the 2001/2002 winter flu season.
The agreement designates MedCenterDirect as the exclusive
electronic distributor of ZstatFlu to Community Health Centers, which
will order ZstatFlu tests through the MedCenterDirect web site at
www.medcenterdirect.com.
"MedCenterDirect will play a very important role in the success of
this initiative by providing a highly efficient ordering process to
ensure the timely delivery of products to Community Health Centers,"
stated Proulx.
MedCenterDirect links clinicians and suppliers through Internet
e-commerce technology. "MedCenterDirect streamlines administrative and
financial functions for providers," said Dr. Curtin. "Its cost-savings
system will allow Community Health Centers to more effectively manage
their medical inventories."
About the Organizations
ZymeTx, Inc., headquartered in Oklahoma City, is a biotechnology
company engaged in the development of technology to produce products
for the diagnosis and treatment of viral disease, viral management and
disease surveillance. The company developed ZstatFlu, the world's
first rapid point-of-care test capable of detecting both Influenza A
and B, and the National Flu Surveillance Network(TM), a network of
physician sites across the country that use ZstatFlu to track
influenza in their communities and practices. Additional information
on ZymeTx and NFSN can be obtained by accessing the web sites at
www.zymetx.com and www.fluwatch.com.
The National Association of Community Health Centers is the
national trade association serving and representing the interests of
America's Community Health Centers, private, not-for-profit,
consumer-directed health care corporations which provide high-quality,
cost-effective and comprehensive primary and preventive care to
medically underserved and uninsured people. This nationwide network of
safety net providers is primarily comprised of health centers which
are supported by federal grants under the U.S. Public Health Service
Act: Community Health Centers, Migrant Health Centers, Health Care for
the Homeless Programs and Public Housing Primary Care Programs.
MedCenterDirect is a leading, fully operational cost management
system giving healthcare providers innovative, cost-effective ways to
purchase healthcare products and supplies. MedCenterDirect's fully
integrated cost management platform links clinicians and
administrators with suppliers in a clinically focused, efficient
procurement process. By electronically streamlining purchasing and
inventory control, it allows caregivers to focus on higher-quality
patient care and administrators to lower costs, improve inventory
turns and ensure purchasing contract compliance. It also provides a
new financial management tool enabling comprehensive analysis of cost
per procedure by a physician, a facility, or an entire health care
network.
This press release may contain forward-looking statements
including statements regarding expected future results of operations,
which are subject to risks and uncertainties. All forward-looking
statements in this press release are based upon historical information
available as of the date of this release. Such historic information
may change or become invalid after the date of this release, and by
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes after
the date of this release. The Company's SEC filings contain additional
discussions about those facts, which could cause actual results to
differ from management's expectations.
--30--LVD/dx*
CONTACT: ZymeTx, Inc.
Susan Hammond, 405/271-1314
www.zymetx.com
or
The Gooden Group, Inc.
Media Relations: Brent Gooden, 405/715-3232
KEYWORD: OKLAHOMA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com
(COMTEX) B: ZYMETX INC - Reverses Decision On Nasdaq Appeal, Reverse
B: ZYMETX INC - Reverses Decision On Nasdaq Appeal, Reverse Split
New York, New York, Jun 28, 2001 (Market News Publishing via COMTEX) -- ZymeTx
officials announced they will not challenge the recent decision by a Nasdaq
review panel to delist the biotech and disease management company's stock and
will not, therefore, pursue a reverse stock split as previously announced.
ZymeTx, Inc. (OTCBB:ZMTX) is a biotech company engaged in viral disease
detection.
"We are focused on several opportunities to secure additional financing and
capital for the Company at this time," commented Norman Proulx, President and
Chief Executive Officer at ZymeTx. "In that regard, we are hopeful on several
fronts and intend to aggressively pursue research advancements and to broaden
the Company's distribution channels, so we will not pursue a reverse stock
split."
The Company reported yesterday the signing of a significant, definitive
agreement with Polaroid Corporation (NYSE:PRD) pertaining to a new viral disease
detection technology with numerous applications.
"Our energies are devoted to the encouraging advancements we are making with the
next-generation viral disease detection and diagnostic platform coming forth
from the scientific work with Polaroid," Proulx said. "We also continue to
cultivate the market in Japan, where our rapid point-of-care flu diagnostic
test, ZstatFlu(R), is making inroads. Challenging the Nasdaq's decision at this
time would distract us from the favorable progress we are making in our research
and marketing," Proulx concluded.
About ZymeTx, Inc.
ZymeTx, Inc., headquartered in Oklahoma City, is a biotechnology company engaged
in the development of technology to produce products for the diagnosis and
treatment of viral disease, viral management and disease surveillance. The
Company developed ZstatFlu(R), the world's first rapid point-of-care test
capable of detecting both Influenza A and B, and the National Flu Surveillance
Network(TM) (NFSN), a network of physician sites across the country that use
ZstatFlu to track influenza in their communities and practices. Additional
information on ZymeTx and NFSN can be obtained by accessing the web sites at
www.zymetx.com and www.fluwatch.com.
This press release may contain forward-looking statements, including statements
regarding expected future results of operations, which are subject to risks and
uncertainties. All forward-looking statements in this press release are based
upon historical information available as of the date of this release. Such
historic information may change or become invalid after the date of this
release, and by making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes after the date
of this release. The Company's SEC filings contain additional discussions about
those facts, which could cause actual results to differ from management's
expectations.
CONTACT: TEL: 405/271-1314 Norman Proulx, ZymeTx, Inc., Oklahoma Cit
MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041.
(C) 2001 Market News Publishing Inc.
-0-
KEYWORD: New York, New York
*** end of story *** |
